- Home
- OXM vs PHAR Comparison
OXM vs PHAR Comparison
Compare OXM & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXM
- PHAR
- Stock Information
- Founded
- OXM 1942
- PHAR 1988
- Country
- OXM United States
- PHAR Netherlands
- Employees
- OXM N/A
- PHAR N/A
- Industry
- OXM Apparel
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- OXM Consumer Discretionary
- PHAR Health Care
- Exchange
- OXM Nasdaq
- PHAR Nasdaq
- Market Cap
- OXM 672.2M
- PHAR 707.9M
- IPO Year
- OXM N/A
- PHAR N/A
- Fundamental
- Price
- OXM $36.98
- PHAR $10.96
- Analyst Decision
- OXM Hold
- PHAR Strong Buy
- Analyst Count
- OXM 6
- PHAR 3
- Target Price
- OXM $55.80
- PHAR $30.00
- AVG Volume (30 Days)
- OXM 391.8K
- PHAR 5.6K
- Earning Date
- OXM 09-10-2025
- PHAR 07-31-2025
- Dividend Yield
- OXM 7.47%
- PHAR N/A
- EPS Growth
- OXM 100.54
- PHAR N/A
- EPS
- OXM 5.14
- PHAR N/A
- Revenue
- OXM $1,511,278,000.00
- PHAR $339,836,000.00
- Revenue This Year
- OXM $0.49
- PHAR $12.88
- Revenue Next Year
- OXM $1.90
- PHAR $8.54
- P/E Ratio
- OXM $7.20
- PHAR N/A
- Revenue Growth
- OXM N/A
- PHAR 22.44
- 52 Week Low
- OXM $36.25
- PHAR $6.73
- 52 Week High
- OXM $105.84
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- OXM 34.42
- PHAR 58.06
- Support Level
- OXM $41.05
- PHAR $9.54
- Resistance Level
- OXM $44.46
- PHAR $10.46
- Average True Range (ATR)
- OXM 2.13
- PHAR 0.37
- MACD
- OXM -0.54
- PHAR 0.10
- Stochastic Oscillator
- OXM 7.16
- PHAR 81.20
About OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.